Schizophrenia research · 2026
Toxoplasma serology: Breaking the diagnostic boundary of schizoaffective disorder? Insights from a comparative peripheral immune marker analysis.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Romeo Bruno, Jeannin Juliette, Lestra Valentine, Martelli Catherine, Amirouche Ammar, Benyamina Amine, Hamdani Nora
Аннотация
BACKGROUND: Toxoplasma gondii (T. gondii) infection has been implicated in the pathophysiology of psychiatric disorders, yet no study has compared its seroprevalence between schizoaffective disorder (SZA) and other psychiatric conditions. This study aimed to compare T. gondii seroprevalence between patients with SZA, schizophrenia (SZ), and bipolar disorder (BD), and to examine whether seropositivity differentially affects innate immune markers across these diagnoses.
METHODS: Overall 144 patients were included in this cross-sectional study. T. gondii seroprevalence was determined and leukocyte counts and derived immune ratios were compared across diagnostic groups according to T.gondii seroprevalence.
RESULTS: T. gondii seroprevalence was significantly higher in SZA (68.8%) as compared to BD (44.2%; p = 0.02), but did not differ significantly from SZ (52.2%; p = 0.2). Relative to SZA, higher neutrophil (p < 0.01) and monocyte (p = 0.02) levels were associated with greater odds of BD, while higher NLR was associated with both BD (p = 0.04) and SZ (p = 0.02), and higher MLR with SZ (p = 0.02). However, none of these associations remained significant after Bonferroni correction. We observed a significant interaction between basophil counts and T. gondii in SZA versus BD (padj < 0.01) and SZ (padj < 0.01), indicating a diagnosis-specific immune modulation.
CONCLUSION: Our findings suggest that T. gondii seroprevalence in SZA is closer to SZ than BD. However, seropositivity appears to affect innate immune markers differently in SZA, without inflammatory activation. This immune profile suggests a unique pathophysiological signature in SZA and warrants further investigation.
METHODS: Overall 144 patients were included in this cross-sectional study. T. gondii seroprevalence was determined and leukocyte counts and derived immune ratios were compared across diagnostic groups according to T.gondii seroprevalence.
RESULTS: T. gondii seroprevalence was significantly higher in SZA (68.8%) as compared to BD (44.2%; p = 0.02), but did not differ significantly from SZ (52.2%; p = 0.2). Relative to SZA, higher neutrophil (p < 0.01) and monocyte (p = 0.02) levels were associated with greater odds of BD, while higher NLR was associated with both BD (p = 0.04) and SZ (p = 0.02), and higher MLR with SZ (p = 0.02). However, none of these associations remained significant after Bonferroni correction. We observed a significant interaction between basophil counts and T. gondii in SZA versus BD (padj < 0.01) and SZ (padj < 0.01), indicating a diagnosis-specific immune modulation.
CONCLUSION: Our findings suggest that T. gondii seroprevalence in SZA is closer to SZ than BD. However, seropositivity appears to affect innate immune markers differently in SZA, without inflammatory activation. This immune profile suggests a unique pathophysiological signature in SZA and warrants further investigation.